Health Condition 1: J45- Asthma
Conditions
Interventions
Intervention1: Terbutaline, Bromhexine, Guaiphenesin, Menthol
: Route of administration: Oral with treatment duration of 7 days
Control Intervention1: Ambroxol: Route of administration: Oral with tre
Sponsors
Glenmark Pharmaceuticals Ltd
Eligibility
Inclusion criteria
Inclusion criteria: Adults with bronchospastic respiratory conditions or bronchial asthma requiring outpatient therapy with bronchodilatory or mucolytic cough formulations.
Exclusion criteria
Exclusion criteria: Patients with Patients with hospitalization in the last four weeks for Uncontrolled asthma or requiring inhaled SABA of >=6 dosages in a day for the last week Patients who have been hospitalized and received antimicrobial therapy within the last 24 hours Patients at high risk for infection with 6Ps; pneumonia, pulmonary embolism, pneumothorax, pleural effusion, pulmonary oedema [heart failure] and paroxysmal atrial tachycardia(arrhythmias)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cough Severity at day 7 Sputum consistency at day 7 Nocturnal awakening frequency (No. of Episodes/night) at day 7Timepoint: Day 7 | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment emergent adverse event rate with Bronchodilator based Cough Formulation and ambroxolTimepoint: Day 7 | — |
Countries
India
Contacts
Public ContactDr K Krishnaprasad
Glenmark Pharmaceuticals Ltd.
Outcome results
None listed